Abstract
Preclinical studies have suggested statins have antiproliferative and anti-metastatic effects on endometrial cancer cells. Similarly, most previous epidemiological studies have reported a better prognosis of endometrial cancer in patients who used statins. In this study, we explored the role of statins in the prognosis of endometrial cancer in women with type 2 diabetes in a hospital-based cohort. This retrospective cohort consisted of 119 women with type 2 diabetes who were diagnosed and treated for endometrial cancer at Oulu University Hospital, Finland, between 2007 and 2014. The patients were classified as statin users (n = 58) and nonusers (n = 61) based on the type of medication they were using at the time of endometrial cancer diagnosis. Statin use showed no association with progression-free survival or overall survival in the whole cohort nor the subgroups with type I or type II histology, in lower or higher body mass index groups, or at an early or advanced stage. The results remained similar in the multivariate analysis after adjusting for the patient’s age, cancer stage, and histology. Furthermore, statin use seemed not to have any association with most of the prognostic factors at the time of endometrial cancer diagnosis.
Highlights
Endometrial cancer is the fifth most common cancer among women worldwide (Ferlay et al, 2019) and the incidence is increasing mostly due to obesity (Raglan et al, 2019)
There were 121 women with Type 2 diabetes (T2D) diagnosed with endometrial cancer between 2007 and 2014
Statin use did not have an association with Progression-free survival (PFS) or overall survival (OS) in patients with T2D diagnosed with endometrial cancer either in the whole population or in the subgroups
Summary
Endometrial cancer is the fifth most common cancer among women worldwide (Ferlay et al, 2019) and the incidence is increasing mostly due to obesity (Raglan et al, 2019). T2D itself seems to be an independent risk factor for endometrial cancer, these two diseases share some other common risk factors in addition to obesity (Liao et al, 2014). Most endometrial cancers are diagnosed at early stages (Morice et al, 2016), and the 5-year survival rate is 95% in early endometrial cancer (Siegel et al, 2019). Survival decreases to as low as 16% in advanced cancer (Siegel et al, 2019). Type I endometrial cancers are more common and have
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
